Back to Market返回行情

RNXT RenovoRx, Inc.

USHealthcare
$1.20-14.29%ClosedMarket Cap: $54.1M

As of 2026-08-17

Why RNXT matters now

RenovoRx, Inc. (RNXT) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.20 with -14.29% on the session and $54.1M in market capitalization; recent performance reads 1-month +14.16% and YTD +9.51%.

The latest financial table shown here is Q1 2026, with revenue of $563.0K, net income of $-3.5M, and EPS of $-0.09. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -33.0%.

The latest indexable market news headline is "RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers" from MarketBeat.

Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes VOLL MARK filing P-Purchase. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

3.11

P/S

23.00

EV/EBITDA

-1.80

DCF Value

$0.92

FCF Yield

-33.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

78.7%

Operating Margin

-864.3%

Net Margin

-824.0%

ROE

-138.6%

ROA

-87.9%

ROIC

-105.9%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$563.0K$-3.5M$-0.09
Q4 2025$238.0K$-2.9M$-0.08
FY 2025$1.1M$-11.2M$-0.32
Q3 2025$266.0K$-2.9M$-0.08

Analyst Ratings

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

Strong Buy: 0Buy: 4Hold: 0Sell: 0Strong Sell: 0
Ascendiant CapitalBuy
2026-06-01
Ascendiant CapitalBuy
2026-04-09
HC Wainwright & Co.Buy
2026-04-08
Ascendiant CapitalBuy
2026-02-17
Ascendiant CapitalBuy
2025-11-21

Trading Activity

Insider Trades

VOLL MARKofficer: Chief Financial Officer
Buy2026-05-21
Agah Ramtindirector, officer: Chief Medical Officer
Sell2026-04-07
Gentry Leesaofficer: Chief Clinical Officer
Sell2026-04-07
VOLL MARKofficer: Chief Financial Officer
Sell2026-04-07
Bagai Shaundirector, officer: Chief Executive Officer
Sell2026-04-07

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

1.00

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.